# A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

Source: https://onco.cc/trials/nct06305767/  
OnCo record `nct06305767` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab, Intismeran autogene and Enfortumab vedotin in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.

## Summary

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) is a phase 1/2 interventional study registered as NCT06305767 by Merck Sharp & Dohme LLC, with 230 participants enrolled, started 2024-03-28 and due to reach its primary completion in 2027-04-23. Interventions recorded: Pembrolizumab, Intismeran autogene, Enfortumab Vedotin and Surgery (RC plus PLND).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06305767
- Phase: 1/2
- Setting: A Phase 1/2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma (MIUC) (INTerpath-005)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 230

## Sources

- ClinicalTrials.gov NCT06305767: https://clinicaltrials.gov/study/NCT06305767

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Enfortumab vedotin](https://onco.cc/drugs/enfortumab-vedotin/), [Intismeran autogene](https://onco.cc/drugs/intismeran-autogene/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06305767.json